ABHD5 Inhibitors
Inhibitors of ABHD5 encompass a variety of chemicals that can interfere with the enzymatic activity of ABHD5 or modulate the pathways in which ABHD5 participates. They achieve this by either directly inhibiting the enzyme or by downregulating the metabolic pathways associated with lipid metabolism. Some inhibitors work by decreasing the levels of intracellular cAMP, which is necessary for the initiation of lipolysis and, by extension, could reduce ABHD5 activity, since ABHD5 is crucial for the mobilization of lipid droplets. Others act as antagonists to PPARs, thereby inhibiting the transcription of genes involved in lipid metabolism and potentially leading to a decrease in ABHD5 expression or activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
Inhibits protein kinase A, decreasing cAMP levels and potentially reducing lipolysis, which could downregulate ABHD5 activity. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
PPARγ antagonist that may downregulate genes involved in lipid metabolism, possibly reducing ABHD5 expression. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
AMPK inhibitor that could prevent the phosphorylation of lipolytic enzymes, thereby affecting ABHD5's role in lipid hydrolysis. | ||||||
GSK 0660 | 1014691-61-2 | sc-203985 sc-203985A | 10 mg 50 mg | $172.00 $695.00 | 14 | |
PPARδ antagonist that might decrease the expression of genes involved in fatty acid oxidation, potentially downregulating ABHD5. | ||||||
BADGE | 1675-54-3 | sc-202487 sc-202487A sc-202487B sc-202487C | 25 g 50 g 100 g 500 g | $38.00 $50.00 $63.00 $189.00 | 3 | |
PPARγ antagonist that could inhibit transcriptional activity of lipid metabolism genes, affecting ABHD5. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Muscarinic antagonist that could decrease cAMP levels through G-protein coupled receptor inhibition, potentially reducing ABHD5 activity. | ||||||
T0070907 | 313516-66-4 | sc-203287 | 5 mg | $138.00 | 1 | |
Potent PPARγ antagonist that may suppress lipid metabolism at the transcriptional level, potentially influencing ABHD5. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
While known as an antiretroviral drug, it has been shown to inhibit AKT phosphorylation, which could affect lipid metabolism and ABHD5 indirectly. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $82.00 $163.00 $296.00 $2050.00 $5110.00 $16330.00 | 51 | |
Known to inhibit protein kinase C, could lead to decreased lipolysis and indirectly downregulate ABHD5. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $148.00 $496.00 | 3 | |
Inhibits carnitine palmitoyltransferase 1 (CPT1) and could decrease fatty acid oxidation, potentially affecting ABHD5. | ||||||